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Tumors are metabolic entities wherein cancer cells adapt their metabolism to their
oncogenic agenda and microenvironmental influences. Metabolically different cancer
cell subpopulations collaborate to optimize nutrient delivery with respect to immediate
bioenergetic and biosynthetic needs. They can alsometabolically exploit host cells. These
metabolic networks are directly linked with cancer progression, treatment, resistance,
and relapse. Conversely, metabolic alterations in cancer are exploited for anticancer
therapy, imaging, and stratification for personalized treatments. These topics were
addressed at the 4th annual meeting of the International Society of Cancer Metabolism
(ISCaM) in Bertinoro, Italy, on 19–21 October 2017.
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INTRODUCTION
Tumors are metabolic entities wherein cancer cells adapt their metabolism to their oncogenic
agenda and microenvironment. This highly adaptive metabolic behavior is fundamental for the
different crucial steps of cancer progression, including the ability to sustain energy-consuming
cell proliferation, migration at distant sites and in different tissues with respect to the tissue
of origin, long-term survival in a quiescent state in hostile conditions and drug resistance. To
address these important aspects of tumor biology, the International Society of Cancer Metabolism
(ISCaM) was founded in 2014 as a logical expansion of the International Society for the Study
of Proton Dynamics in Cancer (ISPDC) that operated from 2009 to 2014. ISCaM’s scope is
to improve communication and to foster collaboration between scientists engaged in acidity,
proton dynamics and all aspects of metabolism in tumors and their microenvironment. On 19–
21 October 2017, ISCaM held its 4th annual meeting in Bertinoro, Italy (1–3). This 3-day event
covered several aspects of cancer metabolism, including interactions between cancer and host cells,
microenvironmental characteristics such as local hypoxia and acidosis, and subcellular functions,
including autophagy, lysosome and mitochondrial deregulation and lipid metabolism. Experts
and trainees in genomics, molecular biology, biochemistry, cell biology, imaging, diagnostics,
computational analysis, and nutrition exchanged their experiences and ideas to foster the
development of effective treatments based on a comprehensive understanding of cancer. In this
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respect, during the opening lecture, Ravid Straussmann
described how bacteria in the tumor microenvironment affect
chemosensitivity. He elegantly demonstrated that tumors are
highly complex ecosystems that include multiple components
of the tumor microenvironment and a tumor microbiome.
The cancer microenvironment and its connection with cancer
metabolism were at the core of ISCaM2017 and were addressed
in 10 thematic oral sessions that were accompanied by solid
informative poster sessions.
MICROENVIRONMENT AND CANCER
METABOLISM
Cancer metabolism generates acidic products that reach the
stroma. Azbeta Hulikova explained that stromal myofibroblasts
absorb protons via anion exchanger 2 and distribute them
across the stroma through gap junctions. Stromal cells thereby
optimize acid distribution in tumors, which facilitates tumor
growth. Exchanges also concern different types of cancer cells.
Indeed, Marie-Luce Vignais showed that mesenchymal cells
establish nanotube connections to transfer mitochondria to
cancer stem cells that gain enhanced oxidative phosphorylation,
proliferation and invasiveness. Next talks focused on stromal
cells. Silvia Lemma first explained that lactate produced by
monocytes and macrophages fuels the osteolytic activity of
osteoclast-like giant cells of the bone marrow. These cells take
up lactate via monocarboxylate transporter 1 (MCT1) and
use it as a source of energy for bone degradation. Lactate can
also fuel pyruvate anaplerosis, as shown by Maria Gkiouli
in breast cancer. Focusing on cancer-associated fibroblasts
(CAFs), Serena Martinelli reported increased glucose and
lactate uptake by succinate dehydrogenase (SDH)-deficient
pheochromocytoma-derived cancer cells when co-cultured with
CAFs. Cancer cells gained increased migratory capabilities and
shifted from collective to individual migration in 3D spheroid
co-cultures. CAFs further induced a lactate-dependent activation
of the sirtuin1/peroxisome proliferator-activated receptor γ
coactivator-1α (SIRT1/PGC1α) axis to boost mitochondrial
metabolism in prostate carcinoma cells, as evidenced by Luigi
Ippolito. In macrophages, Alessandra Castegna reported that
glutamine synthetase represents a potential antimetastatic
target as its inhibition promotes an antimetastatic M2 to M1
shift and activates transcritption factor hypoxia-inducible
factor-1 (HIF-1). Together, these talks illustrated the metabolic
contribution of the tumor microenvironment to cancer
progression.
METABOLIC CONTROL OF CANCER
STEMNESS
Cancer stem cells have important roles in cancer initiation,
progression, and drug resistance. Speakers discussed the crosstalk
between cancer stem cells and the tumor microenvironment,
including hypoxia, local acidosis, and metabolic substrate
availability. Margherita Cortini first described a new cancer
stem cell isolation protocol from osteosarcomas. The team
used 3D models with conditioned medium from mesenchymal
stem cells to highlight the role of acidic pH and hypoxia
on stemness and chemotherapy efficiency. In pancreatic ductal
adenocarcinoma (PDAC), EACR-sponsored lecturer Stephan
J Reshkin focused on the influence of stromal collagen I
on the metabolic phenotype and PDAC stem cells. Tokuhiro
Chano then showed that RAB39A, a member of the RAS
oncogene family, was selectively expressed in cancer cells and
induced by hypoxia. RAB39A and its downstream effector
RXRB are associated with cancer stemness and tumorigenesis.
Concerning metabolic substrates, Martina Poteti showed that
glutamine availability suppressed the expression of oncoprotein
BCR/Abl in leukemia stem cells, rendering them resistant to
BCR/Abl tyrosine kinase inhibitors. Irene Bertolini focused on
microvesicles secreted by neurospheres, which are enriched
in glioma stem cells and increase the growth of recipient
glioblastoma cells. pH regulation through vacuolar (V)-ATPase
was identified to control microvesicle content. Conversely,
cancer cell metabolism can influence cancer stemness, as
illustrated by Alessandro Carrer who reported that acetyl-
CoA production by ATP-citrate lyase and subsequent histone
acetylation are early events in the tumorigenesis of Kras-driven
PDAC.
pH DYNAMICS AND CARBONIC
ANHYDRASE IX (CA9) TARGETING
pH regulation is at the core of tumor metabolism. One important
component of pH regulation is carbonic anhydrase IX (CA9)
that exists both as a transmembrane protein and as a shed
ectodomain circulating in the blood of tumor patients. Silvia
Pastorekova showed that CA9 ectodomain cleavage affects
the cancer cell phenotype and microenvironment. Shonagh
Russell then demonstrated that CA9 overexpression supports
the glycolytic phenotype of cancer cells and increases their
metastatic propensity. Holger M Becker further explained
that CA9 increases the transport activity of MCT1 and
MCT4 through direct interaction, thus facilitating lactate
efflux from hypoxic cancer cells and extracellular acidosis. In
melanoma, Ines Boehme showed that extracellular acidosis
triggers a senescence-like phenotype associated with cell
reprogramming. Gemma Di Pompo further described that
acidity promotes osteolysis, and she suggested anti-acid
approaches to reduce osteolytic cancer lesions. Addressing
additional pH regulatory systems, Agustin Asuaje reported
that voltage-gated proton channel Hv1 is essential for
pH homeostasis and the survival of leukemic Jurkat T
cells. He proposed Hv1 as a target to induce intracellular
acidification. Jessica Iorio further illustrated that inhibitors
of ion channels and transporters modulate intracellular
pH in colorectal cancer cells in an extracellular matrix-
dependent manner that involved the β1-integrin/potassium
channel Kv11.1 complex. At the clinical level, Katsuyuki
Kusuzaki presented a promising trial using acridine orange to
sensitize patients with malignant musculoskeletal tumors to
radiotherapy.
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AUTOPHAGY AND LYSOSOMES
Mila Gugnoni reported that cadherin-6 (CDH6) promotes
the metastatic progression of thyroid cancer. Loss of CDH6
disrupted the cellular architecture and attenuated epithelial-
to-mesenchymal transition (EMT) features of thyroid cancer
cells. CDH6 reduced mitophagy, and mitochondrial fixation
promoted cytoskeleton remodeling, leading to collective cell
migration. A high expression of CDH6 was associated with
a poor prognosis in papillary thyroid carcinoma patients.
Yasmin Yu then reported the activities of a novel, selective
phosphatidylinositol-3-kinase Vps34 inhibitor developed by
Sprint Bioscience, which inhibits autophagy and decreases the
growth of human breast carcinomas. Inhibition of autophagy
by Vps34 inhibitors increased sunitinib sensitivity of breast
cancer cells grown as monolayers and multicellular spheroids.
Together with recent evidence of Vps34-mediated regulation
of cellular metabolism, the new data made this lipid kinase
a new interesting target in oncology and metabolic diseases.
Miriam Martini identified another lipid kinase, PIK3-C2γ, as
a PDAC tumor suppressor. Deletion of the PIK3C2G gene
in the KPC pancreatic cancer mouse model initiated and
promoted tumor development, explaining why low PI3K-C2γ
expression is associated with poor survival and chemoresistance.
Pharmacological inhibition of autophagy in PIK3C2G−/− KPC
tumors led to tumor regression, suggesting that the metabolic
phenotype of PI3K-C2γ-deficient tumors can be exploited
therapeutically.
LIPID METABOLISM
The increasingly recognized importance of lipids in cancer
has recently prompted rapid advances in lipidomics and
related technologies, including mass spectrometry (MS), liquid
chromatography tandem-mass spectrometry (LC-MS/MS) and
nuclear magnetic resonance (NMR) spectroscopy. In response
to stress conditions, cancer cells display strong lipid avidity
and a shift to lipid metabolism through hyperactivation of
lipogenic enzymes, enhancement of de novo lipid synthesis,
increased uptake of exogenous lipids, accumulation of lipid
droplets, and increased lipolysis. Stefania Raimondo showed that
intracellular phospholipase A1 family member DDHD1 supports
colon cancer cell proliferation and survival by modulating
PI3K/Akt and ERK signaling pathways, which can be repressed
with siRNAs against DDHD1. This new target was reported to
be cancer-specific. Anti-angiogenic therapies have a stressing
impact on cancers and may activate lipid metabolism as a
mechanism of resistance to hypoxia. Using LC-MS analysis,
Carolina Venturoli showed that anti-VEGF therapy enhances
the total level of fatty acids and the intracellular concentration
of diacylglycerols and triacylglycerols in xenograft models
of ovarian cancer. However, no changes were observed in
the expression of enzymes involved in fatty acid synthesis
and uptake. Transcriptome analyses rather revealed increased
expression of phospholipase A2, a key enzyme for the release of
fatty acids from glycerol.
MITOCHONDRIA IN CANCER
Mitochondria play a central role in energy metabolism,
biosynthesis, calcium, and redox homeostasis and signaling.
Focusing on redox stress, Götz Hartleben found that mTORC1-
inhibitor tuberous sclerosis 1 (TSC1) ensures homeostasis
between oncogenic factors MYC and mTORC1 through the
repression of both mitochondrial oxygen consumption and
mitochondrial reactive oxygen species (mtROS) production
In Burkitt’s lymphoma cells. Gloria Scattolin further reported
that drugs increasing mtROS production or decreasing mtROS
scavenging induce the death of T-lymphoblastic leukemia
cells via activation of mitochondrial protease OMA1. Beyond
mtROS, Samantha C Higgins tested drug repositioning to
target mitochondrial functions in gliomas. She showed that
tricyclic antidepressant clomipramine induces a cell cycle arrest
in G2/M phase, inhibits complexes I and III of the electron
transport chain (ETC), triggers mitochondrial depolarization,
cytochrome c release and apoptosis. However, upon ETC
complex I inactivation, Luisa Iommarini highlighted that
osteosarcoma cells increased their glycolytic flux, glutamine
carboxylation and lipid metabolism for survival. Cancer is also
a systemic metabolic disease. Indeed, in cachectic muscles of
pancreatic and colorectal cancer patients, Adeline Dolly reported
decreased mitochondrial oxygen consumption linked to energy
production, which reflected strong mitochondrial alterations
in cachectic muscles. Heme is involved in mitochondrial
metabolism and is also a strong pro-oxidant. Veronica
Fiorito found that plasma membrane-bound heme exporter
FLVCR1a controls heme homeostasis in a subpopulation of
colorectal cancer cells, which potentially opens new therapeutic
perspectives.
METABOLIC CONTROL OF CANCER
BEHAVIOR
A fundamental question in cancer metabolism is how limitations
of glucose and glutamine availability affect the metabolic cancer
phenotype. In MCF7 breast cancer cells, Angela M Otto
found that glucose-derived 13C is present in both glycolysis
and TCA-cycle intermediates, varying with the concentrations
and ratios of glucose and glutamine. Especially at limiting
glucose levels, 13C profiles pointed at pyruvate carboxylation
and pyruvate recycling. On the other hand, overexpression of
mitochondrial isocitrate dehydrogenase 2 (IDH2) can perturb
the metabolic balance, which made breast cancer cells more
sensitive to other metabolic impairments. As Georgina D
Barnabas showed, knocking down two enzymes of serine
synthesis, phosphoglycerate dehydrogenase and phosphoserine
aminotransferase, reduced glycolysis and inhibited cancer cell
survival. She proposed new combinations for synthetic lethality.
Amedeo Columbano focused on early hepatocarcinomas, in
which downregulation of succinate dehydrogenase by tumor
necrosis factor receptor-associated protein 1 (TRAP1) during
tumor progression increased MCT4 expression and glucose-
6-phosphate dehydrogenase (G6PDH) activity. Conversely,
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silencing transcription factor NRF2 increased the expression
of miRNA-1, a G6PDH-tageting miR, thus deregulating the
pentose phosphate pathway. Katiuscia Bianchi presented an
interesting novel interaction between the innate immune
system and serine metabolism in tumors, mediated by direct
phosphorylation and transcriptional regulation of enzymes in the
serine biosynthesis pathway. Extracellular ATP, which can also be
a mediator of tumor inflammation, is detected in tumors where it
activates ionotropic receptor P2X7. Lucie Brisson reported that
P2X7 overexpression is associated with metastatic features in
various cancers, supporting P2X7 antagonists as anticancer drug
candidates.
In a second session on the same topic, Elena Piccinin
identified that PGC1β drives metabolic rewiring to promote
hepatocellular cancer progression. A little appreciated issue in
the study of cancer metabolism is the identification of specific
metabolic inhibitors. Several widely used molecules (i.e., 2-
deoxyglucose and 3-bromopyruvate) are indeed not selective
for blocking the glycolytic flux, making the development of
novel drugs an impellent need. To fill this gap, Adam Zweifach
developed a novel screening strategy to pinpoint molecules
specifically blocking glycolysis. Ferdinando Chiaradonna
further described the development of inhibitors targeting
aberrant protein glycosylation in triple-negative breast cancer.
Identification of metabolic targets in cancer has valuable
therapeutic potential, as illustrated by Kiran K Velpula when
targeting pyruvate dehydrogenase kinase 1 in temozolomide-
resistant glioblastoma cells; and Riva Shmulevich who used
KLOTHO, a soluble tumor suppressor, as anticancer treatment.
Identification of proper antimetabolic therapies also requires
analyzing cancer metabolic subtypes. Hence, Michela Menegollo
focused on differential carbon source dependencies of breast
cancer subtypes. Metabolic deregulation in cancer was also
addressed from the systemic standpoint. In particular, Lindsay
A Broadfield reported effects of metformin directly on the
microbiome, which can alter host metabolism.
TARGETING MITOCHONDRIA AND
METABOLISM
New treatments are currently emerging selectively targeting
tumor cell metabolism. Ivana Kurelac presented new data on
ETC complex I inhibition, highlighting decreased activation
of HIF-1 and reduced angiogenesis in complex I-deficient
osteosarcoma and colorectal cancer cells. However, stromal
cells partly rescued angiogenesis. Agnese De Mario focused
on the mitochondrial calcium uniporter (MCU) that gates
mitochondrial calcium uptake. MCU depletion decreased tumor
growth and metastasis, whereas increased mitochondrial calcium
uptake with two compounds newly identified by DeMario’s team
had opposite effects. Christos Chinopoulos reported that highly
glutaminolytic and metastatic glioblastoma VM-M3 cells rely
on a high activity of succinate-coA ligase to produce energy-
rich phosphates when cellular respiration is impaired. Knocking-
down subunit Suclg1 killed the cells, pointing at succinate-
coA ligase as a potential anticancer target. When comparing
responses of glioma and breast cancer cells to metabolic
modulators 2-deoxyglucose, dichloroacetate, and phenformin,
Diana Tavares-Valente identified cell type-specific metabolic
changes indicative of different sensitivities to the treatments.
Nevertheless, pretreatment with these inhibitors sensitized
glioblastoma cells to temozolomide and breast cancer cells to
doxorubicin chemotherapy in vivo, which should prompt further
evaluation of such strategies.
IMAGING OF CANCER METABOLISM
This session covered advanced approaches to understand
the spatial distribution of metabolites in tumors, answering
questions about basic metabolic changes and adaptation to
the tumor microenvironment and about inherent metabolic
heterogeneity. Valery V Khramtsov summarized recent efforts
to use paramagnetic resonance spectroscopy and imaging to
characterize oxygen, pH and inorganic phosphate distribution
in in vivo tumor models. Interestingly, intratumor phosphate
content reflected oxygen supply but not pH, suggesting that
phosphate accumulation reflects mitochondrial activity, while
pH is independent of the hypoxic state of tumors. Annasofia
Anemone reported similar findings using breast cancer xenograft
models and MRI-based approaches to map tumor hypoxia
and acidosis in vivo. Her data suggested that hypoxia and
acidosis are causally associated, but not spatially correlated.
Eleonora Cavallari confirmed the association between lactate
dehydrogenase activity and hypoxia in cancer cells using
MR analysis of hyperpolarized [1−13C]-pyruvate metabolism.
Giuseppe Ferrauto followed by compellingly demonstrating that
multiparametric MRI is a valuable tool for tumor staging,
in particular by providing indirect information about the
“cellularity” of prostate tumors, which correlates with tumor
invasiveness. He also presented a promising novel approach
utilizing the frequency-encoded contrast of chemical exchange
saturation transfer agent YB-HPDO3A for glioblastoma pH
mapping in collaboration with Hana Lahrech. Mikhail M Dikov
closed the session by presenting a novel application of EPR-based
phosphate imaging, complementing the first talk in the session.
He showed how to use these data to predict immune depletion
and the metastatic potential of tumors.
CANCER METABOLISM AND DRUG
RESISTANCE
Tumors can develop metabolic adaptations to cope with the
toxicity of chemotherapeutic agents. Giulia Girolimetti showed
that accumulation of mitochondrial DNAmutations significantly
contributes to resistance to paclitaxel in in vivo tumor models
by altering mitochondrial activity and consequent PGC1α-driven
adaptive mitochondrial biogenesis. Other speakers addressed
the question of whether the usage of different nutrients might
contribute to the regulation of drug sensitivity. For instance,
Sepideh Aminzadeh-Gohari showed that ketogenic diet can
increase the tumor response to combination chemotherapy
in vivo. Novel targets to overcome drug resistance were
Frontiers in Oncology | www.frontiersin.org 4 October 2018 | Volume 8 | Article 329
Avnet et al. Cancer Metabolism
presented as well. Valentina Audrito showed that nicotinamide
phosphoribosyltransferase is a potential target in BRAF-
mutated metastatic melanoma, and Zinger Lotem proposed
that inhibition of the mTORC1/2-Akt axis can counteract anti-
estrogen resistance associated with estrogen receptor-activating
mutations in breast cancer cell lines.
CONCLUSIONS
Cancer metabolism is at the core of cancer research, and
several therapeutic interventions targeting precise metabolic
enzymes, receptors, and transporters are currently reaching
clinical evaluation stages. Accordingly, in the closing lecture,
Antonio Moschetta concluded the ISCaM2017 meeting by
providing a broad overview of the importance of nutrients, genes
and metabolism in cancer, largely exemplified with the case of
hepatocarcinomas.
ISCaM aims to promote interactions between basic and
clinical researchers and between young and senior scientists.
At ISCaM2017, those interactions were facilitated by the
relatively small size of the meeting (132 participants) that
was open to ISCaM members only this year, and by its
international composition (attendees represented 20 countries).
Social activities and meet-the-expert sessions were organized.
Oral and poster communications were dispatched to sessions
focusing on emerging aspects of cancer metabolism that
were co-chaired by a principal and by a young investigator.
Prizes were awarded to young investigators who delivered
best scientific presentations. The best oral presentation prize
went to Mila Gugnoni for her study highlighted above, and
the best poster presentation prize to Alessandra Iscaro for
her study on the microenvironmental control of immune
modulation during carcinoma progression. Travel grants were
also attributed to young scientists based on the scientific merit
of submitted abstracts. The 10 awardees were Agustin Asuaje,
Valentina Audrito, Georgina Barnabas, Lindsay Broadfield,
Alessandro Carrer, Giuseppe Ferrauto, Zinger Lotem, Felipe
Muñoz Cordova, Riva Shmulevich, and Shonag Russell. Finally,
the ISCaM board was renewed at the General Assembly, and
Silvia Pastorekova was appointed President-Elect to ensure the
Presidency of ISCaM from the annual meeting ISCaM2018.
Conclusively, ISCaM2017 provided the audience with most
recent discoveries on metabolic networks in cancer. This
major topic of investigation will continue to be
discussed and updated at the ISCaM2018 meeting
in Bratislava, Slovakia, 17–20 October 2018
(https://www.iscams.org/meeting/iscam2018-%E2%80%93-5th-
annual-meeting-%E2%80%93-metabolic-adaptations-and-
targets-cancer-%E2%80%93-bratislava).
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